RGC

Regencell Bioscience Holdings Limited (RGC) | Rumor.io

Regencell Bioscience Holdings

RGC

Attention (50-day avg)0%

Attention rank (50-day avg)#2,396

Bullish sentiment (50-day avg)96%

Price to earnings ratio-855.6

Market capitalization3.1B

Earnings per share-0.01

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RGC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% -0.02

Jul 21

The CEO of Regencell Bioscience Holdings Limited owns around 90% of shares, which are locked up, and there are zero shares available to short with a 246% borrow fee.
The company's recent offering in late May closed at $20.30 per share, and some believe it may be bought up and trigger a parabolic run.
Regencell Bioscience Holdings Limited's chart has broken a key level, and some believe it may repeat a previous meme run, with the stock potentially breaking above $10 and running for multiple days.

Generated by AI

Sentiment

Of the messages about RGC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +5.56	95% -1.67	89.57% +5.48
Bearish	0%	0% -5.56	5% +1.67	10.43% -5.48

Bullish· Jul 21

The company's recent offering at $20.30 per share suggests that someone is planning to buy up the stock, potentially triggering a parabolic run.
The stock's chart is showing a healthy tape and a reversal pattern that could lead to a multi-day candle, which could be a sign of a big move.
The CEO's 90% ownership of shares and the lack of available shares to short could limit selling pressure and contribute to a potential parabolic run.

Bearish· May 15

* RGC's high short interest and locked-up float due to the CEO's ownership may lead to price volatility.
* RGC's recent price movement may be triggered by China-related news, given its historical correlation with such events.
* RGC's borrow fee has increased to 400% with zero shares available, indicating strong bearish sentiment and potential price drops.

Generated by AI

Topics

Of the messages about RGC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	60%	45.84%
Announcements	0%	0%	40%	16.23%
Earnings	0%	0%	0%	0.34%
Analysts	0%	0%	0%	13.65%
Controversies	0%	0%	0%	0.41%
Macro	0%	0%	0%	23.54%

Earnings· Feb 28

Regal Entertainment Group is set to release Q4 2017 earnings on Thursday, with analysts expecting 0.33 EPS.
The earnings release will occur after the market closes on Thursday.
Analysts are forecasting a specific EPS figure for Regal Entertainment Group's Q4 2017 earnings.

Announcements· Jan 23

Regencell Bioscience Holdings Limited ($RGC) shares surged 40.44% to $30.77, breaking the $25.29 resistance on 1.32M volume.
The company's innovation pipeline is expanding, driven by heightened legal scrutiny from shareholder investigations, signaling pivotal corporate developments.
$RGC's technical breakout is confirmed, with a measured move target of $45.11, driven by a legal catalyst and institutional momentum.

Technical Analysis· Jan 9

$RGC is in a prime A+ setup with high probability and good risk/reward, but shorting was prohibited at the broker.
$RGC needs to break $46 to maintain upward momentum and could experience a large move similar to $VWAV if it breaks above $20.
$RGC has a microcap thin tape, but quiet accumulation could flip into volume ignition with one candle, and traders are setting profit taking at $170.

Generated by AI

Community

Of the messages about RGC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	52.11%	22.95%
Newcomers	0%	0%	47.89%	77.05%

Regulars· Jul 21

The CEO of RGC owns around 90% of shares, which are locked up, making it difficult to short the stock.
A recent offering in late May closed at $20.30 per share, and someone may buy up the stock.
The MACD indicator on the 1-year chart has turned positive, similar to the pattern before the stock's last parabolic run to $70.

Newcomers· Apr 1

The newcomer is optimistic about $RGC's potential to reach $50+ after hours and into tomorrow, drawing parallels with its previous run.
The newcomer is focused on the stock's extreme volatility and high-risk, high-reward scenario, driven by float mechanics and supply chain partnership news.
The newcomer highlights the stock's 23,745% surge in 2025, attributing it to patent portfolio strengthening and an extended lock-up period, which reduces selling pressure.

Generated by AI

News

United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises (NASDAQ:RGC)

2mo agoSeeking Alpha

Also Discussed

Investors talking about RGC also mention

#	Name	Attention
1	KNW - Know Labs, Inc.	——
2	Anbio Biotechnology LtdNNNN	0%0
3	DIST - Distoken Acquisition Corporation	——
4	MicroAlgo Inc.MLGO	0%new
5	Polyrizon Ltd.PLRZ	0%0
6	SMX (Security Matters) Public Limited CompanySMX	0%+0
7	Hyperscale Data, Inc. Class A Common StockGPUS	0.01%+0
8	Vor Biopharma Inc.VOR	0%new
9	Brand Engagement Network Inc.BNAI	0%+0
10	Azitra Inc.AZTR	0%0

Regencell Bioscience Holdings Limited

Healthcare
Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine-based products. Regencell Bioscience Holdings Limited concentrates on treatments for neurocognitive disorders and degeneration, with particular attention to attention deficit hyperactivity disorder and autism spectrum disorder. The company also applies its bioscience platform to infectious diseases that affect the immune system, reflecting a broader therapeutic scope within natural and holistic healthcare. Its product development approach centers on standardized TCM formulations designed for clinical use, positioning the company within the specialty biopharmaceutical segment of the health technology market. Regencell Bioscience Holdings Limited serves as a niche participant in the medical and pharmaceutical landscape by targeting conditions with unmet treatment needs through non-conventional medicine-based research and commercialization.

Website

Location

Chinachem Leighton Plaza

Causeway Bay

Hong Kong

Social

What share of all stock conversation is about RGC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% -0.02

Jul 21

The CEO of Regencell Bioscience Holdings Limited owns around 90% of shares, which are locked up, and there are zero shares available to short with a 246% borrow fee.
The company's recent offering in late May closed at $20.30 per share, and some believe it may be bought up and trigger a parabolic run.
Regencell Bioscience Holdings Limited's chart has broken a key level, and some believe it may repeat a previous meme run, with the stock potentially breaking above $10 and running for multiple days.

Generated by AI

Sentiment

Of the messages about RGC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +5.56	95% -1.67	89.57% +5.48
Bearish	0%	0% -5.56	5% +1.67	10.43% -5.48

Bullish· Jul 21

The company's recent offering at $20.30 per share suggests that someone is planning to buy up the stock, potentially triggering a parabolic run.
The stock's chart is showing a healthy tape and a reversal pattern that could lead to a multi-day candle, which could be a sign of a big move.
The CEO's 90% ownership of shares and the lack of available shares to short could limit selling pressure and contribute to a potential parabolic run.

Bearish· May 15

* RGC's high short interest and locked-up float due to the CEO's ownership may lead to price volatility.
* RGC's recent price movement may be triggered by China-related news, given its historical correlation with such events.
* RGC's borrow fee has increased to 400% with zero shares available, indicating strong bearish sentiment and potential price drops.

Generated by AI

Topics

Of the messages about RGC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	60%	45.84%
Announcements	0%	0%	40%	16.23%
Earnings	0%	0%	0%	0.34%
Analysts	0%	0%	0%	13.65%
Controversies	0%	0%	0%	0.41%
Macro	0%	0%	0%	23.54%

Earnings· Feb 28

Regal Entertainment Group is set to release Q4 2017 earnings on Thursday, with analysts expecting 0.33 EPS.
The earnings release will occur after the market closes on Thursday.
Analysts are forecasting a specific EPS figure for Regal Entertainment Group's Q4 2017 earnings.

Announcements· Jan 23

Regencell Bioscience Holdings Limited ($RGC) shares surged 40.44% to $30.77, breaking the $25.29 resistance on 1.32M volume.
The company's innovation pipeline is expanding, driven by heightened legal scrutiny from shareholder investigations, signaling pivotal corporate developments.
$RGC's technical breakout is confirmed, with a measured move target of $45.11, driven by a legal catalyst and institutional momentum.

Technical Analysis· Jan 9

$RGC is in a prime A+ setup with high probability and good risk/reward, but shorting was prohibited at the broker.
$RGC needs to break $46 to maintain upward momentum and could experience a large move similar to $VWAV if it breaks above $20.
$RGC has a microcap thin tape, but quiet accumulation could flip into volume ignition with one candle, and traders are setting profit taking at $170.

Generated by AI

Community

Of the messages about RGC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	52.11%	22.95%
Newcomers	0%	0%	47.89%	77.05%

Regulars· Jul 21

The CEO of RGC owns around 90% of shares, which are locked up, making it difficult to short the stock.
A recent offering in late May closed at $20.30 per share, and someone may buy up the stock.
The MACD indicator on the 1-year chart has turned positive, similar to the pattern before the stock's last parabolic run to $70.

Newcomers· Apr 1

The newcomer is optimistic about $RGC's potential to reach $50+ after hours and into tomorrow, drawing parallels with its previous run.
The newcomer is focused on the stock's extreme volatility and high-risk, high-reward scenario, driven by float mechanics and supply chain partnership news.
The newcomer highlights the stock's 23,745% surge in 2025, attributing it to patent portfolio strengthening and an extended lock-up period, which reduces selling pressure.

Generated by AI

Regencell Bioscience Holdings

Social

Jul 21

Bullish· Jul 21

Bearish· May 15

Earnings· Feb 28

Announcements· Jan 23

Technical Analysis· Jan 9

Regulars· Jul 21

Newcomers· Apr 1

Regencell Bioscience: I Got It Wrong (Rating Downgrade) (NASDAQ:RGC)

Regencell Bioscience stock hits 52-week low at 4.91 USD

Regencell Bioscience stock hits 52-week low at $5.72

United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises (NASDAQ:RGC)

Also Discussed

Regencell Bioscience Holdings Limited

Company Information

Location

Regencell Bioscience: I Got It Wrong (Rating Downgrade) (NASDAQ:RGC)

Regencell Bioscience stock hits 52-week low at 4.91 USD

Regencell Bioscience stock hits 52-week low at $5.72

United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises (NASDAQ:RGC)

Also Discussed

Social

Jul 21

Bullish· Jul 21

Bearish· May 15

Earnings· Feb 28

Announcements· Jan 23

Technical Analysis· Jan 9

Regulars· Jul 21

Newcomers· Apr 1